<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04435431</url>
  </required_header>
  <id_info>
    <org_study_id>IRL790C005</org_study_id>
    <nct_id>NCT04435431</nct_id>
  </id_info>
  <brief_title>A Clinical Study of Mesdopetam in Patients With Parkinson's Disease Experiencing Levodopa Induced Dyskinesia</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Phase IIB Study Evaluating the Efficacy of Mesdopetam on Daily ON-time Without Troublesome Dyskinesia in Patients With Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Integrative Research Laboratories AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Integrative Research Laboratories AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2b study investigating the efficacy and safety of mesdopetam as adjunct&#xD;
      therapy on daily ON-time without troublesome dyskinesia in patients with Parkinson disease.&#xD;
      Mesdopetam is taken for 84 days.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      At the screening visit consenting patients will be screened for eligibility according to&#xD;
      study specific inclusion/exclusion criteria within 8 weeks before start of Investigational&#xD;
      Medicinal Product (IMP) administration. A diary concordance training will be performed and&#xD;
      following the screening visit the patient will be asked to self-administer three 24-hour home&#xD;
      diaries and to bring the completed diaries to the baseline visit for assessment prior&#xD;
      randomization.&#xD;
&#xD;
      At the baseline visit, patients will be randomized to receive one of three doses of&#xD;
      mesdopetam (dose 1, dose 2 and dose 3) or placebo b.i.d.&#xD;
&#xD;
      During the first week a dose run-in phase will take place, where all patients allocated to&#xD;
      mesdopetam will receive a run-in dose of mesdopetam twice daily and patients allocated to&#xD;
      placebo will receive placebo twice daily. At Visit 2, patients will receive mesdopetam dose&#xD;
      1, dose 2 or dose 3 or placebo b.i.d., as randomized and continue the same dose for the rest&#xD;
      of the treatment period until EOT. Dose reductions are restricted and the dose can only be&#xD;
      reduced once. Dose reductions are permitted from visit 2 (day 9) until visit 3 (day 28),&#xD;
      where after the dose should be kept stable until EOT.&#xD;
&#xD;
      The treatment allocation will be double-blind, i.e. it will not be disclosed to the patients,&#xD;
      the site staff or the Sponsor.&#xD;
&#xD;
      During the treatment period, changes in disease state and ON phase dyskinesia will be&#xD;
      assessed using the MDS-UPDRS, the modified UDysRS (i.e. parts 1, 3 and 4), and Clinician's&#xD;
      Global Impression of Severity (CGI-S). Furthermore, patients will self-administer three&#xD;
      24-hour home diaries prior to visit 3 (week 4), visit 4 (week 8) and visit 5 (week 12) to&#xD;
      assess daily motor function.&#xD;
&#xD;
      Blood samples for pharmacokinetic (PK) analysis will be collected at visit 4 (week 8) and&#xD;
      visit 5 (week 12).&#xD;
&#xD;
      Visit 6 (follow-up) will be performed for all patients, including any patients that&#xD;
      discontinue the IMP early, 5-8 days after last administration of IMP.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 29, 2020</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in average daily hours of ON-time without troublesome dyskinesia with mesdopetam compared to Placebo as assessed with 24-hour patient home diaries from baseline to end of treatment.</measure>
    <time_frame>Baseline to end of treatment (week 12)</time_frame>
    <description>This is a self administered diary where patients assess their motor state every half hour during 24 hours. The different motor states assessed: ON, ON with troublesome dyskinesia, OFF and asleep.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in mean score of ON-phase dyskinesia assessed with the sum score of the modified UDysRS (parts 1, 3 and 4) (with mesdopetam compared to placebo).</measure>
    <time_frame>Baseline to end of treatment (week 12)</time_frame>
    <description>The scoring range is 0-88, where higher score means more dyskinesia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in mean score of disability associated with ON-phase dyskinesia assessed with the sum score of parts 1b and 4 of the UDysRS (with mesdopetam compared to placebo).</measure>
    <time_frame>Baseline to end of treatment (week 12)</time_frame>
    <description>The scoring range is 0-60, where higher score means more dyskinesia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in mean score of ON-phase dyskinesia assessed by MDS-UPDRS part 4 questions 4.1 (Time spent with dyskinesias) and 4.2 (Functional impact of dyskinesias) (with mesdopetam compared to placebo).</measure>
    <time_frame>Baseline to end of treatment (week 12)</time_frame>
    <description>Minimum score is 0 and maximum score is 8. A higher score means more dyskinesia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in mean score of motor symptoms of PD assessed with MDS-UPDRS total score of part 2 (M-EDL) (with mesdopetam compared to placebo)</measure>
    <time_frame>Baseline to end of treatment (week 12)</time_frame>
    <description>Minimum score is 0 and maximum score is 52. A higher score means more motor symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in average daily hours of OFF-time, daily ON-time with troublesome dyskinesia and daily total ON-time (defined as the sum of ON-time with and without troublesome dyskinesia) (with mesdopetam compared to placebo).</measure>
    <time_frame>Baseline to end of treatment (week 12)</time_frame>
    <description>This is a self administered diary where patients assess their motor state every half hour during 24 hours. The different motor states assessed: ON, ON with troublesome dyskinesia, OFF and asleep.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Mesdopetam dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mesdopetam capsule (mg), dose 1, 1 capsule b.i.d. for 84 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mesdopetam dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mesdopetam capsule (mg), dose 2, 1 capsule b.i.d. for 84 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mesdopetam dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mesdopetam capsule (mg), dose 3, 1 capsule b.i.d. for 84 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsule, 1 capsule b.i.d. for 84 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mesdopetam</intervention_name>
    <description>Oral use</description>
    <arm_group_label>Mesdopetam dose 1</arm_group_label>
    <arm_group_label>Mesdopetam dose 2</arm_group_label>
    <arm_group_label>Mesdopetam dose 3</arm_group_label>
    <other_name>IRL790</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral use</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female ≥30 and ≤79 years of age at the time of screening.&#xD;
&#xD;
          2. Signed a current Ethics Committee approved informed consent form (ICF).&#xD;
&#xD;
          3. PD, per UK Parkinson's Disease Society (UKPDS) Brain Bank Clinical Diagnostic&#xD;
             Criteria.&#xD;
&#xD;
          4. Minimal amount of 2 hours of levodopa-induced daily &quot;ON-time with troublesome&#xD;
             dyskinesia&quot; during waking hours&#xD;
&#xD;
          5. Functional impact of dyskinesias determined as a score of ≥2 as per Question 4.2 of&#xD;
             the MDS-UPDRS.&#xD;
&#xD;
          6. On a stable regimen of antiparkinson medications for at least 30 days prior to first&#xD;
             home diary completion which must include a levodopa preparation administered 3-8&#xD;
             times/day (excluding nighttime levodopa) and willing to continue the same doses and&#xD;
             regimens during study participation. Rescue medications such as Madopar dispersable&#xD;
             and Apomorphine injections are allowed if prescribed PRN prior to study entry.&#xD;
&#xD;
          7. Any other current and allowed prescription/non-prescription medications and/or&#xD;
             nutritional supplements taken regularly must have been at a stable dose and regimen&#xD;
             for at least 30 days prior to first home diary completion and the patient must be&#xD;
             willing to continue the same doses and regimens during study participation (this&#xD;
             criterion does not apply to medications that are being taken pre-study only on an&#xD;
             as-needed basis).&#xD;
&#xD;
          8. Able to complete 24-hour patient home diaries of which two valid diaries must be&#xD;
             presented at visit 1.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of neurosurgical intervention related to PD (e.g. deep brain stimulation).&#xD;
&#xD;
          2. Treatment with pump delivered antiparkinsonian therapy (i.e. subcutaneous apomorphine&#xD;
             or levodopa/carbidopa intestinal infusion).&#xD;
&#xD;
          3. History of seizures within two years prior to screening.&#xD;
&#xD;
          4. History of stroke or transient ischemic attack (TIA) within two years prior to&#xD;
             screening.&#xD;
&#xD;
          5. History of cancer within five years prior to screening, with the following exceptions:&#xD;
             adequately treated non-melanomatous skin cancers, localized bladder cancer, non&#xD;
             metastatic prostate cancer or in situ cervical cancer.&#xD;
&#xD;
          6. Presence of cognitive impairment, as evidenced by a Mini-Mental State Examination&#xD;
             (MMSE) score of less than 24 during screening.&#xD;
&#xD;
          7. A Hoehn and Yahr stage of 5.&#xD;
&#xD;
          8. Ongoing treatment with amantadine at time of screening or within 6 weeks prior first&#xD;
             home diary completion.&#xD;
&#xD;
          9. Treatment with Inbrija (levodopa inhalation powder) at time of screening or within 4&#xD;
             weeks prior first home diary completion.&#xD;
&#xD;
         10. Any history of a significant heart condition or cardiac arrhythmias within the past 5&#xD;
             years, any repolarisation deficits or any other clinically significant abnormal ECG as&#xD;
             judged by the Investigator.&#xD;
&#xD;
         11. Severe or ongoing unstable medical condition including a history of poorly controlled&#xD;
             diabetes; obesity associated with metabolic syndrome; uncontrolled hypertension;&#xD;
             cerebrovascular disease, or any form of clinically significant cardiac disease,&#xD;
             clinically significant symptomatic orthostatic hypotension (a fall and/or a&#xD;
             discomfort); clinically significant hepatic disease, severe renal impairment, i.e.&#xD;
             creatinine clearance &lt;30 mL/min (stage IV or V).&#xD;
&#xD;
         12. Any history of a neurological disorder other than PD or a psychiatric disorder,&#xD;
             including history of Diagnostic and Statistical Manual of Mental Disorders (DSM) IV&#xD;
             diagnosed major depression or psychosis. Patients with illusions or hallucinations&#xD;
             with no loss of insight will be eligible. Patients with mild depression who are well&#xD;
             controlled on a stable dose of an antidepressant medication for at least 4 weeks&#xD;
             before screening will be eligible.&#xD;
&#xD;
         13. Enrolment in any other clinical study involving medication, medical devices or&#xD;
             surgical procedures, current or within three months prior to screening visit, or&#xD;
             previous participation in the present study. Patients enrolled in non-interventional&#xD;
             clinical trials will be eligible.&#xD;
&#xD;
         14. Drug and/or alcohol abuse.&#xD;
&#xD;
         15. History of severe drug allergy or hypersensitivity.&#xD;
&#xD;
         16. If female, is pregnant or lactating, or has a positive pregnancy test result pre-dose.&#xD;
&#xD;
         17. Patients unwilling to use two forms of contraception (one of which being a barrier&#xD;
             method (see Section 8.1) during the treatment period and 90 days for men and 30 days&#xD;
             for women after last IMP dose.&#xD;
&#xD;
         18. Any planned major surgery within the duration of the study.&#xD;
&#xD;
         19. Any other condition or symptoms preventing the patient from entering the study,&#xD;
             according to the Investigator's judgement.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joakim Tedroff</last_name>
    <role>Study Director</role>
    <affiliation>Integrative Research Laboratories AB (IRLAB)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joakim Tedroff/Chief Medical Officer</last_name>
    <phone>+46707601691</phone>
    <email>joakim.tedroff@irlab.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maria Jalmelid/Chief of Clinical Operations</last_name>
    <phone>+46730757706</phone>
    <email>maria.jalmelid@irlab.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Collaborative Neuroscience Research (CNS Research)</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Movement Disorders Center</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Parkinson's Disease and Movement Disorders Center of Boca Raton</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Elias Research Associates (Allied Biomedical Research Institute)</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pharmax Research of South Florida, Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33175</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>USF Parkinson's Disease and Movement Disorders Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Kentucky, Department of Neurology</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Regional Universitaire de Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Dupuytren 1 - Neurologie</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Carémeau</name>
      <address>
        <city>Nimes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Rennes-Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Charles Nicolle; Service de Neurologie</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rambam Health Care Campus, Department of Neurology</name>
      <address>
        <city>Haifa</city>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hadassah University Hospital-Ein Kerem, Department of Neurology</name>
      <address>
        <city>Jerusalem</city>
        <zip>9112001</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Centre - Beilinson Hospital, Department of Neurology</name>
      <address>
        <city>Petah Tikva</city>
        <zip>4941492</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Chaim Sheba Medical Centre, Department of Neurology</name>
      <address>
        <city>Ramat Gan</city>
        <zip>5265601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Sourasky Medical Centre; Movement Disorders Unit</name>
      <address>
        <city>Tel Aviv</city>
        <zip>6423906</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>IRCCS - Ospedale &quot;San Martino&quot;</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Padova</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>IRCCS San Raffaele Pisana</name>
      <address>
        <city>Roma</city>
        <zip>00163</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico Gemelli IRCCS</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>AOU San Giovanni di Dio e Ruggi d'Aragona, Clinica Neurologica</name>
      <address>
        <city>Salerno</city>
        <zip>84131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Neuromed</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-163</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Specjalistyczna Praktyka Lekarska</name>
      <address>
        <city>Katowice</city>
        <zip>40-097</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne PLEJADY</name>
      <address>
        <city>Kraków</city>
        <zip>30-363</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Specjalistyczne Gabinety Sp z o.o.</name>
      <address>
        <city>Kraków</city>
        <zip>30-539</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Krakowska Akademia Neurologii</name>
      <address>
        <city>Kraków</city>
        <zip>31-505</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instytut Zdrowia</name>
      <address>
        <city>Oświęcim</city>
        <zip>32-600</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Next Stage sp.z o.o.</name>
      <address>
        <city>Warsaw</city>
        <zip>02-042</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Center Zvezdara, Clinical department of Neurology</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Clinical Center of Serbia, Clinic for Neurology</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Serbia</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Becanovic K, Vittoria de Donno M, Sousa VC, Tedroff J, Svenningsson P. Effects of a Novel Psychomotor Stabilizer, IRL790, on Biochemical Measures of Synaptic Markers and Neurotransmission. J Pharmacol Exp Ther. 2020 Jul;374(1):126-133. doi: 10.1124/jpet.119.264754. Epub 2020 May 1.</citation>
    <PMID>32358047</PMID>
  </reference>
  <reference>
    <citation>Waters S, Sonesson C, Svensson P, Tedroff J, Carta M, Ljung E, Gunnergren J, Edling M, Svanberg B, Fagerberg A, Kullingsjö J, Hjorth S, Waters N. Preclinical Pharmacology of [2-(3-Fluoro-5-Methanesulfonyl-phenoxy)Ethyl](Propyl)amine (IRL790), a Novel Dopamine Transmission Modulator for the Treatment of Motor and Psychiatric Complications in Parkinson Disease. J Pharmacol Exp Ther. 2020 Jul;374(1):113-125. doi: 10.1124/jpet.119.264226. Epub 2020 May 1.</citation>
    <PMID>32358046</PMID>
  </reference>
  <reference>
    <citation>Svenningsson P, Johansson A, Nyholm D, Tsitsi P, Hansson F, Sonesson C, Tedroff J. Safety and tolerability of IRL790 in Parkinson's disease with levodopa-induced dyskinesia-a phase 1b trial. NPJ Parkinsons Dis. 2018 Dec 6;4:35. doi: 10.1038/s41531-018-0071-3. eCollection 2018.</citation>
    <PMID>30534585</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 15, 2020</study_first_submitted>
  <study_first_submitted_qc>June 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 17, 2020</study_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Dyskinesias</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

